Truist Securities Downgrades PROCEPT BioRobotics to Hold, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 92.6%

Neg 92.6% Neu 0% Pos 0%

Truist Securities analyst Richard Newitter downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Buy to Hold and lowers the price target from $30 to $25.